secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001714899-24-000215
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q3 net loss $107.2M; tividenofusp BLA planned early 2025; DNL126 shows biomarker reduction
--------------------------------------------------------------------------------

- Net loss $107.2M vs $99.4M YoY; no collaboration revenue; cash $1.28B at Sep 30, 2024.
- Updated 2024 cash opex guidance: +5-10% vs 2023 (prior: ≤2023) due to BLA prep and commercial readiness.
- Tividenofusp alfa (MPS II): FDA agrees CSF HS as surrogate endpoint; BLA submission on track for early 2025.
- DNL126 (MPS IIIA): preliminary data show CSF HS reduction and normalization; study expanded for accelerated path.
- SAR443820/DNL788 (MS): Sanofi's K2 Phase 2 discontinued after missing primary and key secondary endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000215/0001714899-24-000215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000215/dnli-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer